These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17486268)

  • 1. More than eight years' hands-on experience with the novel long-acting parenteral testosterone undecanoate.
    Saad F; Kamischke A; Yassin A; Zitzmann M; Schubert M; Jockenhel F; Behre HM; Gooren L; Nieschlag E
    Asian J Androl; 2007 May; 9(3):291-7. PubMed ID: 17486268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone depot injection in male hypogonadism: a critical appraisal.
    Yassin AA; Haffejee M
    Clin Interv Aging; 2007; 2(4):577-90. PubMed ID: 18225458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
    Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
    J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of various modes of androgen substitution therapy on erythropoiesis.
    Jockenhövel F; Vogel E; Reinhardt W; Reinwein D
    Eur J Med Res; 1997 Jul; 2(7):293-8. PubMed ID: 9233903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testosterone undecanoate in the treatment of male hypogonadism.
    Edelstein D; Basaria S
    Expert Opin Pharmacother; 2010 Aug; 11(12):2095-106. PubMed ID: 20642374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
    Behre HM; Abshagen K; Oettel M; Hübler D; Nieschlag E
    Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men.
    Qoubaitary A; Meriggiola C; Ng CM; Lumbreras L; Cerpolini S; Pelusi G; Christensen PD; Hull L; Swerdloff RS; Wang C
    J Androl; 2006; 27(6):853-67. PubMed ID: 16837736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
    Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
    J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido).
    Yassin AA; Saad F
    World J Urol; 2006 Dec; 24(6):639-44. PubMed ID: 17048032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
    Minnemann T; Schubert M; Hübler D; Gouni-Berthold I; Freude S; Schumann C; Oettel M; Ernst M; Mellinger U; Sommer F; Krone W; Jockenhövel F
    Aging Male; 2007 Sep; 10(3):155-8. PubMed ID: 17701659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.
    Saad F; Gooren L; Haider A; Yassin A
    Andrologia; 2008 Feb; 40(1):44-8. PubMed ID: 18211301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.
    Zitzmann M; Nieschlag E
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3844-53. PubMed ID: 17635942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of long-acting parenteral testosterone undecanoate compound in the induction of secondary sexual characteristics in males with hypogonadotropic hypogonadism.
    Giagulli VA; Triggiani V; Carbone MD; Corona G; Tafaro E; Licchelli B; Guastamacchia E
    J Sex Med; 2011 Dec; 8(12):3471-8. PubMed ID: 21995803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
    Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.